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Background: Glucose-6-phosphate dehydrogenase deficiency (G6PDd) is widespread across malaria endemic
regions. G6PD-deficient individuals are at risk of haemolysis when exposed, among other agents, to primaquine and
tafenoquine, which are capable of blocking malaria transmission by killing Plasmodium falciparum gametocytes and
preventing Plasmodium vivax relapses by targeting hypnozoites. It is evident that no measures are currently in place
to ensure safe delivery of these drugs within the context of G6PDd risk. Thus, determining G6PDd prevalence in
malarious areas would contribute towards avoiding possible complications in malaria elimination using the drugs.
This study, therefore, was aimed at determining G6PDd prevalence in Gambella hospital, southwest Ethiopia, using
CareStart™ G6PDd fluorescence spot test.
Methods: Venous blood samples were collected from febrile patients (n = 449) attending Gambella hospital in
November-December 2013. Malaria was diagnosed using blood films and G6PDd was screened using CareStart™
G6PDd screening test (Access Bio, New Jersey, USA). Haematological parameters were also measured. The association
of G6PD phenotype with sex, ethnic group and malaria smear positivity was tested.
Results: Malaria prevalence was 59.2% (96.6% of the cases being P. falciparum mono infections). Totally 33 participants
(7.3%) were G6PD-deficient with no significant difference between the sexes. The chance of being G6PD-deficient
was significantly higher for the native ethnic groups (Anuak and Nuer) compared to the ‘highlanders’/settlers
(odds ratio (OD) = 3.9, 95% confidence interval (CI) 0.481-31.418 for Anuak vs ‘highlanders’; OD = 4.9, 95% CI
0.635-38.00 for Nuer vs ‘highlanders’). G6PDd prevalence among the Nuer (14.3%) was significantly higher than
that for the Anuak (12.0%).
Conclusions: G6PDd prevalence in the area is substantial with 30 (90.9%) of the 33 deficient individuals having
malaria suggesting the non-protective role of the disorder at least from clinical malaria. The indigenous Nilotic
people tend to have a higher chance of being G6PD-deficient as 32 (96.9%) of the total 33 cases occurred among
them.
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Despite some reduction in the global burden of malaria
in recent years [1], the disease still stands a grave public
health concern. Apart from multiple environmental and
parasite factors that complicate human-Plasmodium in-
teractions, human genetic background confers additional
complexity in the fight against malaria [2]. A high degree
of variation exists between human populations and indi-
viduals with respect to malaria incidence, parasite density
and disease severity and reactions to anti-malarials [3]. Al-
though in some studies glucose-6-phosphate dehydrogen-
ase deficiency (G6PDd) is associated with protection from
severe malaria [4,5] deficient individuals are reported to
suffer from haemolytic anaemia when treated with prima-
quine [6], which is the only available drug against Plasmo-
dium falciparum gametocytes [7] and a radical cure of
Plasmodium vivax [8]. Further individuals with G6DPd
are reported to suffer from haemolysis when treated with
tafenoquine, another anti-malarial with proposed indica-
tion of treating hypnozoites of P. vivax and Plasmodium
ovale [9].
G6PDd is one of the most common human enzymopa-
thies which is in a very high frequency in tropical and sub-
tropical malaria endemic regions [10,11]. In sub-Saharan
Africa (SSA), the prevalence of G6PDd can reach up to
35% although organized reports are lacking and different
allelic variants are unevenly distributed in the region
[12]. However, with progressive improvements in detec-
tion methods past G6PDd prevalence figures may need
continuous revision. Population screening is recommended
in regions where G6PDd prevalence is ≥3–5% to decide
on the use of primaquine/tafenoquine and minimize
the risk of primaquine/tefenoquine-induced complica-
tions in malaria elimination schemes [13]. In Ethiopia,
past population-based G6PDd studies are limited and the
practice of G6PDd screening in healthcare settings is also
missing. As a result, vital information on G6PDd preva-
lence is lacking in the country, especially in malaria en-
demic foci. This study, therefore, was aimed at bridging
the gap by diagnosing G6PDd among malaria suspects
attending Gambella hospital, southwest Ethiopia, using a
qualitative rapid G6PDd screening kit.
Methods
Study area
The study was conducted in Gambella hospital, Gambella
Town. The town is the administrative center of Gambella
Regional State and is located in the southwest of Ethiopia
at about 777 km from Addis Ababa. Gambella hospital
which serves an estimated 200,000 patients is the only
hospital in the Region when this study was conducted.
Gambella Region borders with Benishangul Gumuz and
Oromiya Regions in the north; with the Southern Nations,
Nationalities and Peoples’ Region (SNNPR) and the Sudanto the south; Oromiya and SNNPR to the east and the
Sudan to the west. The region has an area of 25,800 km2
with an estimated total population of 42,474 having six
major native Nilotic ethnic groups, namely, Anuak (also
called Anywaa), Nuer, Majenger, Opo, Surma and Komo
[14]. The Nuer and the Anuak are the dominant groups in
the region and in Gambella Town settlers of various eth-
nic origins who moved from all over Ethiopia are loosely
defined as “highlanders”.
The town is a lowland area with average altitude of
300–500 metres above sea level and has latitude and
longitude of 8°15′00″ N and 34°34′59″ E, respectively.
The main rainy season of the region is between May and
October, and from November through April it is mostly
dry [15]. According to this same source [15], the mean
annual temperature of the region ranges from 17.3 to
28.3°C and the annual monthly temperature vary between
27 and 33°C throughout the year. The absolute maximum
and minimum temperatures are 45.0 and 10.3°C occurring
in mid-March and December, respectively. The average
yearly rainfall is 1200 millimetre. Subsistence cultivation
of maize and sorghum along the sides of the major rivers -
Baro, Akobo and Gilo - is practiced by the Anuak. Fishing
and forest hunting may be supplementary income sources.
Most Nuers who mainly live in the driest Ethio-Sudanese
border of the region largely depend on livestock [16].
Gambella is characterized by high malaria transmission
due to its suitable climate and high rainfall. P. falciparum
and P. vivax contribute to most of the malaria cases of the
general population and Anopheles gambiae and Anopheles
pharoensis are the primary mosquito vector species [17].
Some Plasmodium malariae cases were also reported
from Gambella in an extensive epidemiological study in
the late 1960s [18].
Study population and design
Asymptomatic individuals for G6PDd but suspected of
malaria (axillary temperature ≥37.5°C) were recruited in
a hospital-based cross-sectional study between mid-
November and December 2013. Patients who had received
anti-malarial treatment within the past 48 hours and those
having chronic illnesses were excluded. The minimum
sample size (n) for the study was calculated using the for-
mula n ¼ Z2  P 1‐Pð ÞmZ [19]; where ‘Z’ is standard normal
distribution curve value for the 95% confidence interval
(CI) (Z = 1.96), ‘p’ estimate prevalence (0.5%) and ‘m’ 5%
margin of error (0.05). With a response rate of 96%, the
estimated sample size was 400.
Sample collection and analysis
After a questionnaire and clinical examination, 5 ml ven-
ous blood was collected in ethylene diamine tetra acetic
acid (EDTA) for measuring haematological parameters,
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logical parameters - haemoglobin (Hb), haematocrit (HCT)
and packed cell volume (PCV) - and red cell indices (mean
corpuscular volume (MCV), mean corpuscular haemoglo-
bin (MCH) and mean corpuscular haemoglobin concen-
tration (MCHC) were determined using an automated
system, CELL-DYN 1400 haematology analyzer (Abbott,
USA). Thick and thin blood smears were prepared and
stained using 10% Giemsa solution to detect malaria. The
stained slides were examined under a light microscope
using the oil immersion objective (100X). Two experi-
enced laboratory technologists independently screened
the slides and discrepancies were settled by a third per-
son’s blind test. Parasite density was calculated per 200
white blood cells (WBC) assuming 8,000 WBC/μl of blood
[20]. G6PDd was screened using CareStart™ G6PDd
screening test (Access Bio, Inc., New Jersey, USA) following
the manufacturer’s instruction. Briefly, a 2 μl whole blood
was added to a sample well and then 100 μl of assay buffer
to the buffer well immediately after application of blood.
The result was read normal as distinct purple colour, defi-
cient as no colour or a very faint purple colour; and invalid
when there is no blood migration or incomplete blood mi-
gration in the reading window within 10 minutes.
Data analysis
Data were entered in Microsoft Excel spreadsheet,
checked for correctness and completeness, and exported
to and analysed using statistical package for social sci-
ences (SPSS) version 20 (SPSS IBM, Chicago, IL). The
Chi-squared (X2) test was used to determine the associ-
ation between occurrence of malaria and G6PD status.
Difference between means of haematological parame-
ters for G6PD-deficent and normal individuals was
analysed by analysis of variance (ANOVA). The logistic
regression model was used to determine the relation-
ship between sex and ethnic group with G6PD-deficent
phenotype.
Ethical clearance
The study obtained ethical clearance from College of
Natural Sciences Institutional Ethics Review Board, Addis
Ababa University. The study participants were recruited
after providing their voluntary informed consent. Health
personnel examined the patients, collected blood sample
and treated malaria positives free of charge as per the na-
tional treatment guideline.
Results
Overall, 510 febrile patients were prescribed for malaria
blood smear during the study period. Fourteen individ-
uals who declined to participate and 47 who had re-
ceived anti-malarial treatment within the past 48 hours
prior to sample collection were excluded. Thus bloodsamples from 449 patients, 210 males and 239 females,
were analysed. The mean age was 16 years, median 15 and
range 1–90 years; and mean haemoglobin (Hb) was
14.02 g/dl and median 13.3 g/dl, with no significant differ-
ence between the sexes. Overall, 266(59.2%) individuals
were malaria smear positive with 257(96.6%) P. falciparum
mono, 7(2.6%) P. vivax mono and 2(0.75%) P. falciparum/
P. vivax mixed infections. Thirty three (7.3%) individuals
were deficient for G6PD enzyme activity (Table 1). Al-
though the prevalence of G6PDd was slightly higher
among males (8.6%) than females (6.3%), the difference
was not statistically significant (p = 0.354). In a univariate
logistic analysis, the odds of being G6PD-deficient were
1.4 times higher for males [95% CI 0.678-2.853] than for
females but the difference was not statistically significant
(p > 0.05). However, the occurrence of G6PDd varied be-
tween ethnic groups. A greater proportion of the Nuer were
G6PD-deficient (14.3%) compared to the ‘highlanders’
combined, who were all non-deficient except a single
Kambata. The 12.0% G6PDd prevalence among the
Anuak was also substantial compared to the almost nil
‘highlanders’. The differences were statistically significant
in both cases (p < 0.0001). The odds of being G6PD-
deficient were 4.9 [95% CI 0.635-38.00] and 3.9 [95% CI
0.481-31.418] times higher for the Nuer and Anuak ethnic
groups compared to the ‘highlanders’, respectively (p <
0.0001) (Table 2). When the G6PDd prevalence for the
Nuer and Anuak was compared from within the difference
was also significant.
While G6PD-deficient males who were malaria smear
positive were 94.4% (17/18), females of the same cat-
egory were 87.6% (13/15). Thirty (90.9%) out of the 33
G6PD-deficient participants were malaria smear positive
which was significantly higher than the incidence of
malaria among normal individuals for the enzyme (p <
0.0001). However, the mean parasite density of G6DP-
deficient individuals (1.64 (±1.55) was significantly lower
than that of G6DP-normal individuals (2.97 (±1.22) (p <
0.0001). Similarly, the mean Hb concentration in G6DP-
deficient individuals (14.15 (±3.50) was significantly higher
than that of normal ones (12.44 (±2.70) (p = 0.006).
Further, the mean HCT of G6PD-deficient individuals
(37.86 (±8.609) was significantly higher than that of nor-
mal participants (43.13 (±10.54) (p = 0.005). But the mean
values of MCV, MCH and MCHC were not significantly
different between the two groups (p > 0.05) (Table 3).
Seven (21.2%), 1 (3.0%), 9 (27.2%) and 7 (21.2%) indi-
viduals were macrocytic, microcytic, hypochromic and
microcytic-hypochromic, respectively, among the G6PD-
deficient (Table 4). From the non-deficient; 31 (7.4%),
4 (0.96%) 78 (18.7%) and 29 (6.7%) were macrocytic,
microcytic, hypochromic and microcytic-hypochromic
respectively. The differences between the two groups
for the respective parameters were significant.
Table 1 Prevalences of G6PDd among outpatients of Gambella hospital, southwest Ethiopia by malaria status, sex and
ethnic group, 2013





















Normal Male 192 117 (60.9) 75 (39.0) 38 (19.7) 59 (30.7) 22 (11.4) 21 (10.9) 14 (7.3) 16 (8.3) 11 (5.7) 11 (5.7)
Female 224 119 (53.1) 105 (46.8) 42 (18.7) 67 (29.9) 24 (10.7) 20 (8.9) 27 (12.0) 10 (4.4) 18 (8.0) 16 (7.1)
Deficient Male 18 17 (94.4) 1 (5.5) 7 (14.5) 10 (55.5) 00 (0.0) 00 (0.0) 00 (0.0) 00 (0.0) 1 (5.5) 00 (0.0)
Female 15 13 (86.7) 2 (13.3) 4 (26.6) 11 (73.3) 00 (0.0) 00 (0.0) 00 (0.0) 00 (0.0) 00 (0.0) 00 (0.0)
Total 449 266 (59.2) 183 (40.8) 91 (20.2) 147 (32.7) 46 (10.2) 41 (9.1) 41 (9.1) 26 (5.8) 30 (6.6) 27 (6.0)
p-value 0.354 0.000 0.000
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In this study, P. falciparum, P. vivax and mixed infec-
tions accounted for 96.6, 2.6 and 0.8% of malaria cases,
respectively, indicating the overwhelming occurrence of
P. falciparum in the study population. This result is com-
parable to a previous report in the area [21] which was
88.9% for P. falciparum and 11.1% for P. vivax cases.
However, the overall malaria prevalence reported by these
authors was much lower (13.5%) than that of the current
study (59.2%). On the other hand, results from elsewhere
in Ethiopia attribute only 60–70% of the cases to P. falcip-
arum and the rest to P. vivax [22,23]. The high malaria
prevalence in this study shows that the disease is a year-
round problem in Gambella despite the undergoing con-
trol activities and the fact that the survey was conducted
outside the peak transmission season. This may suggest
that either the control strategies in use are ineffective and/
or some specific local predisposing factors to malaria are
impacting. Malaria prevalence did not significantly correl-
ate with participant age or sex but ethnic group. The Nuer
and Anuak were more frequently infected compared toTable 2 Logistic regression analysis of sex and ethnic group f
Gambella hospital, southwest Ethiopia, 2013
Binary logistic regression
UOR (95% CI) p-val
Gender
Female 1
Male 1.4000 (0.678-2.853) 0.354
Ethnic group
Nuer 4.9 (0.635-38.00) 0.000







G6PDd: glucose-6-phosphate dehydrogenase; AOR: adjusted odds ratio, UOR: unadjthe ‘highlanders’ combined. Environmental and differences
in exposure to infectious mosquito bites, among other
things, may account for this apparent difference.
The prevalence of G6PDd was 7.3% in this study. This
figure is relatively lower compared to the world health
organization (WHO) report for SSA which is as high as
35% [12]. The prevalence of G6PDd significantly varies
among different countries and regions or even localities for
several reasons [24,25]. For instance, in southern European
countries, such as Greece [26] and Italy [27], G6PDd
prevalence ranges from 1–30 and 0–3% respectively. A
study in India reported G6PDd prevalence of 27.5% in
males and 12.8% in females [28]. G6PDd prevalence in
Yemen was 7.1% [29] and in the neighbouring Saudi
Arabia it was 9.05% [30]. It is widely believed that isolated
populations have higher G6PDd cases [26,31].
Although the frequency of G6PDd was higher in males
(4.0%) than in females (3.3%) in the present study, the
difference was not statistically significant. Since the gene
of the enzyme is on the X-chromosome and males are
hemizygous, a single allele of the gene would suffice toor G6PDd among malaria suspect outpatients in
Multiple logistic regression











usted odds ratio, CI: confidence interval.
Table 3 Mean ± SD parasitaemia, Hb, HCT and RBC indices in relation to G6PD status among malaria suspected
outpatients in Gambella hospital, southwest Ethiopia, 2013
G6PD Status Parasite density/log10 μl Hb (g/dl) HCT (%) MCV (fl) MCH (pg) MCHC (%)
Normal 2.97 ± 1.22 12.44 ± 2.70 37.86 ± 8.609 85.51 ± 6.68 26.87 ± 5.58 31.98 ± 2.50
Deficient 1.64 ± 1.55 14.15 ± 3.50 43.13 ± 10.54 85.75 ± 5.84 28.12 ± 4.92 32.43 ± 1.43
p-value 0.000 0.006 0.005 0.834 0.201 0.149
G6PD: glucose-6-phosphate dehydrogenase; Hb: haemoglobin concentration; HCT: haematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular
haemoglobin; MCHC: mean corpuscular haemoglobin concentration; RBC: red blood cell; SD: standard deviation.
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frequency of the deficient phenotype is expected in males
than in females. Since females inherit two copies of the
X-chromosome and therefore have two populations of
red blood cells (RBCs), each expressing one of the two
G6PD alleles they carry (homozygous females), two defi-
cient alleles are required to render them G6PD-deficient
phenotypically. From this point of view, the present study
seems to be contrary to what is theoretically expected.
However, diagnosing heterozygote females that express
two different RBC populations (normal and deficient) to
the enzymatic activity level is highly challenging, as the
deficiency can be masked by cells expressing normal activ-
ity. G6PDd is relatively reliably detected in males [32,33]
and diagnostics for heterozygous females are altogether
more complex and uncertain. That is perhaps why G6PDd
in females is underreported in many epidemiological stud-
ies. Indeed there are studies that reported a narrow vari-
ation of G6PDd prevalence between boys and girls with a
p-value just slightly below the 0.05 level [34].
The prevalence of G6PDd significantly varied between
ethnic groups in Gambella area; the highest frequency be-
ing among the indigenous Nuer and Anuak ethnic groups.
This must be taken into account in planning primaquine/
tafenoquine use to eliminate malaria especially in the rural
areas of Gambella where the natives exclusively reside. A
similar study in Nigeria recorded some variation in G6PDd
with respect to ethnic affiliation though the effect was not
significant possibly due to the relatively small number of
non-Yoruba children in the study, as the authors suggested
[35]. In a study from India the G6PDd prevalence ranged
from 0 to 27% and a clear variation was noted between dif-
ferent castes, tribes and ethnic groups [36].
The significantly higher occurrence of malaria smear
positivity among G6PD-deficient individuals, compared
to the non-deficient, observed in this study suggests lackTable 4 Prevalence of various anaemia types and G6PD statu







Normal 31 (7.4) 4 (0.96)
Deficient 7 (21.2) 1 (3.0)
p-value 0.000 0.316of correlation between G6PDd and protection from clin-
ical malaria. But the significantly lower mean parasite
density, higher Hb and HCT values among the deficient
shows the protective role of G6PDd against severe mal-
aria. In fact, the literature is not concordant regarding
the role of G6PDd in malaria. G6PDd was associated
with protection against severe malaria in males but not in
heterozygous females [37]. Contrarily, others reported the
protection of heterozygous females but not the hemi/
homozygous with a more severe degree of G6PDd [38].
Still there is evidence for protection from symptomatic
malaria for both hemi/homozygous and heterozygous indi-
viduals [39]. G6PDd is weakly associated with asymptom-
atic malaria infection [40,41]. High malaria parasitaemia
and mortality was observed among G6PD-deficient pa-
tients in Iran [42]. In another recent study the odds of mal-
aria infection was not significantly lower in children with
the deficient phenotype [34]. In vitro studies are equally
conflicting [43,44]. Since G6PD expression is vital for sur-
vival of Plasmodium inside the host cell the parasite may
synthesize its own G6PD within deficient RBCs [45]. This
may partially explain why G6PDd is not associated with
protection from malaria at least in some settings including
the present one. The method of G6PDd assessment can
possibly affect the association studies of malaria suscepti-
bility due to G6PDd [46].
It is well-known that G6PDd contributes to macrocytic,
microcytic and hypochromic anaemia. In microchromic
anaemia the RBC are usually also hypochromic. Further,
rapid RBC turnover from G6PDd haemolysis can trigger
mild macrocytosis. This may explain the significantly
higher proportion of G6PD-deficent individuals for these
different types of anaemia compared to the non-deficient
in the present study. However, the results should be inter-
preted with caution as there are several other causes of





78 (18.7) 29 (6.7)
9 (27.2) 7 (21.2)
0.000 0.000
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thies and overall health status may influence G6PD activ-
ity [47]. Since the MCV and MCH values for microcytic
(MCV <80 fL), macrocytic (MCV >96 fL) and hypochro-
mic (MCH <27 pg) anaemia are comparable especially
with that of thalassaemia [48], it may be misleading to
conclude that the asymptomatic G6PDd is responsible for
the observation in this study. Although little specific infor-
mation is available concerning haemoglobinopathies in
general, Gambella is part of the global thalassaemia map
[49]. Thus, future studies are warranted to clearly under-
stand the role of asymptomatic G6PDd on haematological
parameters and malaria in relation to haemoglobinopa-
thies in the study area. Though rapid qualitative tests
such as the CareStart™ G6PDd screening tests seem
more feasible for mass screening in remote endemic areas
genotyping G6PD and various haemoglobinopathies is
also necessary to explore the local variants. Overall, com-
prehensive understanding of the relationship between
primaquine/tafenoquine dose and risk of G6PDd-related
haemolysis is required to allow deploying or withholding
these drugs in future malaria control or eradication plans
in the study area and beyond.
Conclusions
G6PDd prevalence as determined by measuring the
phenotype (enzyme activity), is considerable among the
indigenous Nilotic population. Despite control efforts
being made, malaria remains highly prevalent among
outpatients in Gambella hospital questioning the efficacy
of control strategies in use. There was no significant
association between G6PDd and protection from malaria
incidence per se. The G6PDd report presented here can
contribute to the evidence-base for weighing risk and
benefit in formulating primaquine/tafenoquine treatment
strategies that could greatly accelerate the elimination of
malaria transmission in the study area. Population-based
genotyping could be important to identify the distribution
of dominant variants in the region.
Limitations of the study
The study did not use quantitative or semi-quantitative
screening methods such as spectrophotometric ultravio-
let (UV). As a result, the WHO’s five classes (levels) of
G6PD activity could not be determined among the study
participants. Besides, because of the fact that a molecular
method was not used, the underlying prevalent variants
and specific mutations in the G6PD-deficient individuals
could not be addressed.
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